Peer-reviewed veterinary case report
Outcome of lymphoma treatment in dogs with single or divided
By Jih-Jong Lee et al.·Published in Topics in Companion Animal Medicine·2020·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcome of Canine Multicentric Lymphoma after Single or Divided Treatment with Cyclophosphamide in Multidrug Chemotherapy.
- Species:
- dog
Plain-English summary
A group of 72 dogs with multicentric lymphoma (a type of cancer) was treated with cyclophosphamide, a common chemotherapy drug. Some dogs received the medication in a single large dose, while others got it in smaller doses spread over several days. Unfortunately, neither method reduced the risk of bladder irritation or bleeding (hemorrhagic cystitis), and both groups had similar outcomes in terms of how long they lived and how well the treatment worked. This means that changing the way cyclophosphamide is given did not improve the situation for these dogs.
People also search for: dog lymphoma treatment options · cyclophosphamide side effects in dogs · dog bladder bleeding after chemotherapy
Abstract
Cyclophosphamide is commonly used in combination chemotherapy to treat dogs with lymphoma. The metabolite of cyclophosphamide, acrolein, can irritate urinary bladder and cause sterile hemorrhagic cystitis. Dividing the administration of cyclophosphamide across multiple days may reduce the concentration of this metabolite in urinary bladder and reduce the possibility of cystitis. However, the impact of the therapeutic effect of this modification is not evaluated and compared to traditional single maximum-tolerated dose regimen. Seventy-two dogs with multicentric lymphoma received either bolus doses or divided doses of cyclophosphamide were included in this study. The incidence of hemorrhagic cystitis between 2 cyclophosphamide treatment groups was not significantly different (P = .357). There was no statistical difference in progression-free survival and survival time between 2 groups (P = .267 and P = .346). This modification of cyclophosphamide administration did not reduce the side effect of cystitis or affect remission and survival times in lymphoma dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/32823160